CRISPR Therapeutics CRSP Increase Decrease In Operating Lease Assets And Liabilities
Increase Decrease In Operating Lease Assets And Liabilities at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept crsp:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's increase decrease in operating lease assets and liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's increase decrease in operating lease assets and liabilities?
- CRISPR Therapeutics (CRSP) reported increase decrease in operating lease assets and liabilities of -$1.52M in Q1 2026.
- How has CRISPR Therapeutics's increase decrease in operating lease assets and liabilities changed year-over-year?
- CRISPR Therapeutics's increase decrease in operating lease assets and liabilities decreased by 32.1% year-over-year, from -$1.15M to -$1.52M.
- What is the long-term trend for CRISPR Therapeutics's increase decrease in operating lease assets and liabilities?
- Over 3 years (2022 to 2025), CRISPR Therapeutics's increase decrease in operating lease assets and liabilities has grown at a -30.2% compound annual growth rate (CAGR), from $15.31M to -$5.21M.
- What does increase decrease in operating lease assets and liabilities mean?
- Reflects the net change in operating lease-related assets and liabilities, primarily driven by the recognition of right-of-use assets and corresponding lease obligations. This metric adjusts operating cash flow for non-cash lease accounting impacts under current standards. It is essential for understanding the company's fixed-cost commitments and real estate footprint.